ESMO 2019 | Health-related QoL in ipilimumab treated advanced melanoma survivors

Christian Blank

Christian Blank, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses the health-related quality of life of advanced melanoma survivors treated with ipilimumab (CTLA-4 immune checkpoint inhibition) at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video